Unbalanced reporting of benefits and harms in abstracts on rofecoxib

[1] Bresalier RS(2005)Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 1092-1102

[2] Sandler RS(2001)Family physicians’ use of medical abstracts to guide decision making: style or substance? J Am Board Fam Pract 14 437-442

[3] Quan H(2008)CONSORT for reporting randomised trials in journal and conference abstracts Lancet 371 281-283

[4] Bolognese JA(2007)What have we learned from Vioxx? BMJ 334 120-123

[5] Oxenius B(1999)Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis Ann Rheum Dis 58 257-259

[6] Horgan K(1999)Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions Am J Pathol 155 1281-1291

[7] Lines C(1999)Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids J Pharmacol Exp Ther 289 735-741

[8] Riddell R(1999)Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 Proc Natl Acad Sci USA 96 272-277

[9] Morton D(2006)Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone J Clin Rheumatol 12 17-25

[10] Lanas A(2000)Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 1520-1528

[1] Bresalier RS(2005)Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 1092-1102

[2] Sandler RS(2001)Family physicians’ use of medical abstracts to guide decision making: style or substance? J Am Board Fam Pract 14 437-442

[3] Quan H(2008)CONSORT for reporting randomised trials in journal and conference abstracts Lancet 371 281-283

[4] Bolognese JA(2007)What have we learned from Vioxx? BMJ 334 120-123

[5] Oxenius B(1999)Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis Ann Rheum Dis 58 257-259

[6] Horgan K(1999)Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions Am J Pathol 155 1281-1291

[7] Lines C(1999)Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids J Pharmacol Exp Ther 289 735-741

[8] Riddell R(1999)Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 Proc Natl Acad Sci USA 96 272-277

[9] Morton D(2006)Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone J Clin Rheumatol 12 17-25

[10] Lanas A(2000)Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 1520-1528